-
1.发明公开公开(公告)号：US20240216495A1
公开(公告)日：2024-07-04
申请号：US18446883
申请日：2023-08-09
申请人： Pfizer Inc.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
CPC分类号： A61K39/08 , A61K9/19 , A61K2039/545
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
2.发明申请公开(公告)号：US20200254081A1
公开(公告)日：2020-08-13
申请号：US16647124
申请日：2018-09-14
申请人： Pfizer Inc.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
3.发明公开公开(公告)号：US20230218735A1
公开(公告)日：2023-07-13
申请号：US18001953
申请日：2021-06-17
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , William Carl Gruber , Kathrin Ute Jansen , Lakshmi Khandke , Nicholas Randolph Everard Kitchin , Jody Lawrence , Yahong Peng , Michael William Pride , Christopher Frederick Webber , Sabine Susanne Wellnitz , Zhuobiao Yi
CPC分类号： A61K39/08 , A61K47/26 , A61K9/19 , C07K16/1282 , A61P31/04 , A61K2039/55577
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US20220160859A1
公开(公告)日：2022-05-26
申请号：US17594107
申请日：2020-03-30
申请人： Pfizer Inc.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , Nicholas Randolph Everard Kitchin , Paul Liberator , Michael William Pride , Christopher Frederick Webber
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
